PANTOGAM
Russian nootropic and neuroprotective GABA derivative used for cognitive, anxiety, and hyperkinetic disorders.
Pantogam has been studied primarily in Russian clinical settings across diverse populations including children with ADHD, adults with hypertension-related cognitive decline, and schizophrenia patients on antipsychotics. A randomized placebo-controlled trial in children aged 6-12 demonstrated significant reduction of hyperkinetic symptoms over 6 weeks versus placebo. Animal studies show it modulates D2 and GABA-B receptor density in the prefrontal cortex of attention-deficit mice. Clinical trials report cognitive and anxiety improvements within the first week of treatment. However, the evidence base is largely confined to Russian-language publications and lacks large-scale international multicenter trials, limiting generalizability. No addiction, hyperstimulation, or withdrawal syndrome has been reported across studies.